A promising 12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance, comparable to conventional pacemaker. This study was reported by Indian origin researcher Vivek Reddy, MD, Director of Arrhythmia Services for The Mount Sinai Hospital.
Dr. Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco, CA.
Advertisement
The LEADLESS study's long-term follow-up has evaluated 32 patients with a slowed heartbeat, bradycardia, who successfully received St. Jude Medical's Nanostim leadless pacemaker at two hospitals in Prague and one in Amsterdam.
The findings, which assessed device performance and patient outcomes through 12-months of follow-up, show pacing thresholds (0.43 volts) and sensing (10.32 mV) of the leadless pacemaker device are equivalent to those in traditional pacemakers. In addition, there was no experience of infections or failure to sense, pace, or communicate with the pacemaker.
![Silent Atrial Fibrillation Increases Risk of Stroke]( "Silent Atrial Fibrillation Increases Risk of Stroke")
People suffering from subclinical atrial fibrillation, as detected by a pacemaker or defibrillator, are at an increased risk of suffering from stroke, according to the ASSERT study.
"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology and our results show the leadless pacemaker is comparable to traditional pacemakers," Dr. Vivek Reddy, Director of Arrhythmia Services at The Mount Sinai Hospital who is the study's co-investigator and Chairman of its Steering Committee, said.
"Our latest findings further support the promising performance and safety of this minimally-invasive, non-surgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits, and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials," he said.
In February, Dr. Reddy was the first to implant the leadless pacemaker in the United States at The Mount Sinai Hospital launching the multicenter clinical trial LEADLESS II which aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the US and Canada.
The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein.
The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than ten percent the size of a traditional pacemaker.
It works by closely monitoring the heart's electrical rhythms and if the heart beat is too slow it provides electrical stimulation therapy to regulate it.
Source: ANI
Silent Atrial Fibrillation Increases Risk of Stroke
People suffering from subclinical atrial fibrillation, as detected by a pacemaker or defibrillator, are at an increased risk of suffering from stroke, according to the ASSERT study.
Advertisement
"This is the first time we've seen one-year follow-up data for this innovative, wireless cardiac pacing technology and our results show the leadless pacemaker is comparable to traditional pacemakers," Dr. Vivek Reddy, Director of Arrhythmia Services at The Mount Sinai Hospital who is the study's co-investigator and Chairman of its Steering Committee, said.
"Our latest findings further support the promising performance and safety of this minimally-invasive, non-surgical pacing device. More long-term follow-up of these LEADLESS study patients will further our understanding of the potential advantages, benefits, and complication risks of leadless pacemaker technology, along with additional ongoing, larger trials," he said.
In February, Dr. Reddy was the first to implant the leadless pacemaker in the United States at The Mount Sinai Hospital launching the multicenter clinical trial LEADLESS II which aims to further test the leadless pacemaker more widely for safety and efficacy in 670 patients at 50 centers across the US and Canada.
The miniature-sized, leadless cardiac pacemaker is placed directly inside a patient's heart without surgery during a catheter-guided procedure through the groin via the femoral vein.
The device, resembling a tiny, metal silver tube and smaller than a triple-A battery, is only a few centimeters in length, making it less than ten percent the size of a traditional pacemaker.
It works by closely monitoring the heart's electrical rhythms and if the heart beat is too slow it provides electrical stimulation therapy to regulate it.
Source: ANI
Depression can be Treated by Deep Brain Stimulation
Depression is a serious medical concern that adversely affects one's behavior, attitude and sentiments. Recent researches reveal that Deep Brain Stimulation can be used to treat depression.
Advertisement
 Arrhythmias or Brain Aneurysm - Treatment is the SameFor the very first time, a technique normally used to treat brain aneurysms, is now used to treat life-threatening arrhythmias. | Advertisement
|
Advertisement
Latest Heart Disease News
Researchers uncovered an association between heart disease and chronic kidney disease.
How to predict heart disease risk? Machine learning algorithms using indicators of oral infections may accurately predict the possibility of heart disease.
A higher risk for earlier first birth is limited by acting on traditional heart disease risk factors, such as BMI, high cholesterol and high blood pressure.
A new study strengthens evidence linking low dose radiation to risk of heart diseases.
People with an irregular heart rhythm (atrial fibrillation or AFib) are at a higher risk of developing dementia.